Wall Street Zen downgraded shares of Lexeo Therapeutics (NASDAQ:LXEO – Free Report) from a sell rating to a strong sell rating in a research report report published on Saturday,Wall Street Zen reports.
LXEO has been the subject of several other reports. Chardan Capital raised shares of Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, November 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Lexeo Therapeutics in a report on Thursday, November 12th. Leerink Partners restated an “outperform” rating and issued a $15.00 price target on shares of Lexeo Therapeutics in a research note on Wednesday, September 23rd. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Lexeo Therapeutics in a research note on Tuesday, September 22nd. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $16.43.
Check Out Our Latest Report on Lexeo Therapeutics
Lexeo Therapeutics Trading Up 12.5%
Shares of Lexeo Therapeutics stock opened at $3.23 on Friday. Lexeo Therapeutics has a 52-week low of $2.55 and a 52-week high of $10.99. The company has a 50 day moving average of $3.35 and a 200 day moving average of $4.99.
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.10). On average, research analysts predict that Lexeo Therapeutics will post -1.22 EPS for the current fiscal year.
Hedge Funds Weigh In On Lexeo Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC purchased a new position in shares of Lexeo Therapeutics in the 2nd quarter valued at $6,932,175. Frazier Life Sciences Management L.P. raised its stake in Lexeo Therapeutics by 9.0% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,824,725 shares of the company’s stock worth $22,459,000 after acquiring an additional 400,000 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in Lexeo Therapeutics during the 2nd quarter worth $1,237,000. Nantahala Capital Management LLC purchased a new stake in Lexeo Therapeutics in the second quarter valued at $6,051,500. Finally, Bank of America Corp DE purchased a new stake in Lexeo Therapeutics in the second quarter valued at $2,282,000. 60.67% of the stock is currently owned by hedge funds and other institutional investors.
Top Lexeo Therapeutics Stories
Here are a few of the latest stories about LXEO:
- Positive Sentiment: In the Phase 1/2 HEROIC-PKP2 trial, the 10 treated participants had clinically meaningful reductions in abnormal heart rhythms. High-dose participants showed an average 80% reduction in non-sustained ventricular tachycardia and a 44% reduction in premature ventricular contractions; the company also reported improvements in right-ventricular function and patient-reported symptoms. LX2020 was generally well tolerated, with no clinically significant complement activation reported. Company trial and earnings update
- Positive Sentiment: The FDA is open to using guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint that could support a potential accelerated-approval pathway. Lexeo expects to begin a pivotal study in late 2027. Benzinga trial update
- Negative Sentiment: Third-quarter EPS was a loss of $0.43, missing analyst expectations for a loss of $0.33, a financial setback alongside the clinical progress. MarketBeat earnings report
About Lexeo Therapeutics
Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.
Further Reading
- Five stocks we like better than Lexeo Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
